Research progress in the treatment of chronic fatigue syndrome through interventions targeting the hypothalamus-pituitary-adrenal axis.
Zhang, Yi-Dan, Wang, Li-Na · Frontiers in endocrinology · 2024 · DOI
Quick Summary
This review examines how ME/CFS affects the body's stress-response system, called the HPA axis, which controls cortisol (a stress hormone). Research shows that people with ME/CFS tend to have lower cortisol levels, less natural variation in cortisol throughout the day, and a weaker response to stress compared to healthy people. Understanding these hormone changes may help explain why ME/CFS patients experience extreme fatigue and other symptoms, and could guide new treatments.
Why It Matters
Understanding HPA axis dysfunction is critical because the stress-response system regulates energy, immune function, and sleep—all severely disrupted in ME/CFS. This review consolidates evidence linking hormonal abnormalities to symptoms, which could inform development of targeted treatments and explain why some patients don't respond to standard fatigue therapies. It provides a biological framework that validates ME/CFS as a physiological disorder rather than purely psychiatric.
Observed Findings
ME/CFS patients demonstrate reduced baseline cortisol levels compared to controls
Flattened diurnal cortisol variation (reduced normal peak-trough pattern)
Diminished HPA axis response to physiological and psychological stressors
Enhanced negative feedback regulation of the HPA axis
Correlation between HPA dysfunction severity and intensity of fatigue and other characteristic symptoms
Inferred Conclusions
HPA axis dysfunction is a consistent neuroendocrine feature in ME/CFS and contributes to symptom manifestation
Targeting the HPA axis through pharmacological or other interventions may represent a viable therapeutic strategy
Neuroendocrine abnormalities likely interact with immune and metabolic dysfunction to produce the ME/CFS phenotype
Remaining Questions
Why do some ME/CFS patients show HPA abnormalities while others do not, and does this reflect distinct disease subtypes?
What is the precise temporal relationship between HPA dysfunction onset and ME/CFS symptom development—is it causative or consequential?
Which HPA-targeted interventions (cortisol replacement, CRF antagonists, etc.) are most effective and for which patient subgroups?
What This Study Does Not Prove
This review does not establish that HPA axis dysfunction is the sole cause of ME/CFS or that it is present in all patients—the authors note significant controversy and variability across studies. It does not prove that correcting cortisol levels will cure ME/CFS, only that associations exist. The review cannot determine whether HPA changes are primary drivers of illness or secondary consequences of systemic dysfunction.